AIP
AARD

Ameritas Investment Partners’s Aardvark Therapeutics AARD Stock Holding History

Ameritas Investment Partners’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18K Hold
578
– – ﹤0.01% 3065
2025
Q4 		$7.59K Hold
578
– – ﹤0.01% 2965
2025
Q3 		$7.68K Hold
578
– – ﹤0.01% 2996
2025
Q2 		$7.82K Buy
+578
New +$5.96K ﹤0.01% 3040

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ameritas Investment Partners's AARD Position: Q1 2026 in Review

Ameritas Investment Partners held its Aardvark Therapeutics (AARD) position steady in Q1 2026 at 578 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Ameritas Investment Partners first reported a position in AARD in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.82K in Q2 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Ameritas Investment Partners held 578 shares of Aardvark Therapeutics worth $2.18K as of Q1 2026.
  • Ameritas Investment Partners left its Aardvark Therapeutics share count unchanged in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #3065 holding.
  • Ameritas Investment Partners first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameritas Investment Partners's Aardvark Therapeutics position peaked at $7.82K in Q2 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.